Germany's Fresenius and Fresenius Medical Care experience stock price decline as Novo Nordisk halts trial with promising early results.
Major Chinese companies, including Alibaba, saw substantial gains following reports of potential stimulus plans. The effectiveness of the measures remains uncertain but offers hope for the future.
FDA rejects approval application for Alnylam's drug, causing stock price drop. Concerns over clinical effectiveness of Onpattro's new indication. Alnylam disappointed but remains determined.
Anaptys reports positive results in Phase 3 trial for imsidolimab, showing rapid clearance of pustulation, erythema, and scaling in patients with generalized pustular psoriasis. The drug also has a favorable safety profile. Future plans inc...
Citigroup plans to sell its onshore consumer wealth portfolio in China to HSBC Holdings as part of its exit strategy in Asia, contributing to HSBC's expansion in the country.